Immune thrombocytopenia: who needs treatment and why
- Treatment and support
In ITP the immune system destroys platelets. Many patients, especially children, need no treatment at all; the bleeding, not the number, decides.
What it is
Immune thrombocytopenia (ITP) is an autoimmune fall in platelets below 100 × 10⁹/L, from antibodies that speed platelet destruction and also slow their production. It is primary when no cause is found and secondary when linked to another illness (lupus, antiphospholipid syndrome, CLL, HIV, hepatitis C, H. pylori, drugs). It is called newly diagnosed in the first 3 months, persistent from 3 to 12 months and chronic after 12 months. In children it usually follows a viral infection and resolves; in adults it more often becomes chronic.
What to know
- Children with skin bleeding only are usually observed, whatever the count; most recover within months.
- Adults are usually treated when the count is very low (commonly below about 30 × 10⁹/L) or when there is bleeding.
- First line: a short course of corticosteroids; intravenous immunoglobulin when a fast rise is needed (bleeding, surgery, delivery).
- Second line: thrombopoietin receptor agonists (romiplostim, eltrombopag), rituximab or splenectomy, chosen with the patient.
- Life-threatening bleeding: immunoglobulin, intravenous steroids and platelet transfusion together, with tranexamic acid.
How it is done (and why)
- Confirm ITP by exclusion: smear (no clumps, no abnormal cells), HIV and hepatitis C tests, and look for secondary causes.
- Grade bleeding: skin only, mucosal (mouth, nose, heavy periods) or serious (gut, brain).
- Decide whether to treat by bleeding, count, age, planned procedures, lifestyle and other drugs (anticoagulants, antiplatelets).
- If treating: short steroid course; add immunoglobulin for a faster rise.
- Relapse or no response after about 3 months: discuss thrombopoietin receptor agonists, rituximab or splenectomy.
- Before splenectomy, vaccinate against pneumococcus, meningococcus and Haemophilus; it is usually delayed a year after diagnosis, as some recover.
The treatment ladder
| Option | How it works | Speed | Main use or limit |
|---|---|---|---|
| Observation | Waits for spontaneous recovery | - | Most children; adults with safe counts and no bleeding |
| Corticosteroids | Reduce antibody-coated platelet destruction | Days | First line; keep courses short to limit side effects |
| Intravenous immunoglobulin | Blocks the spleen's receptors that capture coated platelets | 1–3 days | Bleeding, before surgery or delivery; effect is temporary |
| Thrombopoietin receptor agonists | Drive the marrow to make more platelets | 1–2 weeks | Persistent or chronic ITP; ongoing treatment |
| Rituximab | Removes the B cells that make the antibodies | Weeks | Second line; infection risk, vaccines before |
| Splenectomy | Removes the main destruction site | Days | Lasting response in many; lifelong infection risk |
Risks and precautions
- Long or repeated steroid courses cause diabetes, bone loss, mood change and infections; guidelines limit their length.
- Thrombopoietin receptor agonists can raise the risk of clots and need liver tests (eltrombopag) and count checks.
- After splenectomy, fever is an emergency because of overwhelming infection with encapsulated bacteria.
- In pregnancy, mild low platelets late in a normal pregnancy are usually gestational thrombocytopenia, not ITP; delivery planning with the obstetric and anaesthesia teams matters for both.
Monitoring and next step
- At diagnosis: count, smear, HIV, hepatitis C, and in adults consider H. pylori testing, blood group (for anti-D) and immunoglobulins.
- A marrow is not needed in typical ITP; it is done if the smear or other counts are abnormal, the patient is older, or treatment fails.
- On treatment: count weekly at first, then less often; blood glucose and blood pressure on steroids.
- Before rituximab: hepatitis B tests, because it can reactivate the virus.
Common traps
- Transfusing platelets routinely in ITP: they are destroyed within hours; save them for life-threatening bleeding.
- Treating a well child with skin bruising only because the count is low: a low count alone is not a reason to treat.
- Keeping adults on steroids for months to hold the count up: move to second-line treatment instead.
- Calling it ITP without checking for HIV, hepatitis C, lupus or drugs: the cause changes the treatment.
Test yourself
Think of the answer, then tap the question to see it.
Why do patients with ITP usually bleed less than patients with the same count from marrow failure?
ITP platelets are young and large, released quickly by a working marrow, and work better than the older platelets of a failing marrow.
How does intravenous immunoglobulin raise the platelet count quickly in ITP?
It blocks the Fc receptors on spleen macrophages that capture antibody-coated platelets, so fewer are destroyed for a few weeks.
A five-year-old has petechiae two weeks after a cold, platelets of 15 × 10⁹/L and no mucosal bleeding. What is the usual management?
Observation with advice on warning signs: most childhood ITP resolves on its own, and treatment does not change the outcome when bleeding is mild.
Why is a hepatitis B test done before rituximab?
Rituximab removes B cells and can reactivate hidden hepatitis B, causing severe hepatitis.
Elsewhere in DurgiPedia
- Immune thrombocytopenias: ITP and HIT
- Thrombocytopenia: mechanisms
- Megakaryocytes and how platelets are made
- Neutropenia and low platelets: infection and bleeding precautions, and fever as an emergency
- Bleeding and clotting disorders: haemophilia, ITP and watching for DIC
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Immune thrombocytopenic purpura (ITP) (MedlinePlus, US National Library of Medicine, 2026); Thrombocytopenia (National Heart, Lung, and Blood Institute (NHLBI), 2024); Immune Globulin Intravenous (Human)(IVIG): MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2025); Platelet Disorders | MedlinePlus (MedlinePlus, US National Library of Medicine, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
